iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 201 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR What People With Cancer and Survivors Should Know About Vaping: An... September 26, 2023 Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... June 29, 2021 Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... March 21, 2019 Load more HOT NEWS FDA Approves Injectable Nivolumab, an Alternative to IV Infusion For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Health inequalities: breaking down barriers to cancer screening New on NCI’s Websites for September 2021
